Oncolytics Biotech (NASDAQ: ONCY) CEO awarded 755,000 options at $1.06 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ONCOLYTICS BIOTECH INC reported a Form 4 for Chief Executive Officer Jared Kelly showing a compensation-related grant of stock options. He received options for 755,000 common shares at an exercise price of $1.06 per share, equal to the Nasdaq closing price on June 1, 2026.
The options expire on June 1, 2036 and vest in three equal annual installments starting on June 1, 2027, contingent on continued service. Following this award, his reported stock option holdings from this grant total 755,000 options.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kelly Jared
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 755,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option — 755,000 shares (Direct, null)
Footnotes (1)
- The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.
Key Figures
Options granted: 755,000 options
Exercise price: $1.06 per share
Expiration date: June 1, 2036
+2 more
5 metrics
Options granted
755,000 options
Stock option grant to CEO on June 1, 2026
Exercise price
$1.06 per share
Equal to Nasdaq closing price on June 1, 2026
Expiration date
June 1, 2036
Option term for this award
Post-grant option holdings from this award
755,000 options
Total stock options following the reported transaction
Vesting schedule
Three equal annual installments
First tranche vests June 1, 2027, subject to continued service
Key Terms
Stock Option, exercise price, vests in three equal annual installments, expiration date, +1 more
5 terms
Stock Option financial
"The reported security is a Stock Option linked to common shares."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests in three equal annual installments financial
"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027."
expiration date financial
"The stock option has an expiration date of June 1, 2036."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Nasdaq Capital Market financial
"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant."
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
FAQ
What insider transaction did ONCY CEO Jared Kelly report on this Form 4?
Jared Kelly reported receiving 755,000 stock options as a compensation grant. These options give him the right to buy common shares at a fixed price, rather than reflecting an open-market purchase or sale of existing ONCY shares.
What is the exercise price of Jared Kelly’s new ONCY stock options?
The exercise price of the new stock options is $1.06 per share. This price equals the closing price of ONCOLYTICS BIOTECH’s common stock on the Nasdaq Capital Market on the grant date of June 1, 2026, according to the filing footnote.
How many ONCY stock options did the CEO hold after this reported grant?
After this grant, Jared Kelly is reported as holding 755,000 stock options from this award. These options are derivative securities linked to ONCOLYTICS BIOTECH common shares and represent potential future equity if exercised at the stated exercise price.
When do Jared Kelly’s ONCY stock options vest and become exercisable?
The stock options vest in three equal annual installments beginning on June 1, 2027. Vesting is conditioned on Jared Kelly’s continued service or employment on each vesting date, meaning the full 755,000 options become exercisable gradually over a three-year period.
When do the newly granted ONCY stock options to the CEO expire?
The granted stock options expire on June 1, 2036. If Jared Kelly does not exercise the options by that expiration date, they will lapse and no longer provide the right to purchase ONCOLYTICS BIOTECH common shares at the $1.06 exercise price.
Does this ONCY Form 4 show a market purchase or sale by the CEO?
This Form 4 reflects a grant of stock options as compensation, not a market trade. The transaction code “A” indicates an award or other acquisition, and the transaction price is shown as $0.00, distinguishing it from open-market buying or selling of shares.